DECHRA PHARMACEUTICA

DPH
Delayed Quote. Delayed  - 05/26 11:35:18 am
3552GBX +1.78%
Valuation
Fiscal Period: June 2021 2022
Capitalization1 4 7293 783
Enterprise Value (EV)1 4 9293 945
P/E ratio 85,6x51,3x
Yield 0,93%1,26%
Capitalization / Revenue 7,78x5,70x
EV / Revenue 8,11x5,94x
EV / EBITDA 27,7x20,8x
Price to Book 7,47x6,12x
Nbr of stocks (in thousands) 108 215108 389
Reference price (GBP) 43,734,9
Announcement Date 09/06/2021-
Previous period Next period
1 GBP in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: June 2021 2022
Net sales1 608664
EBITDA1 178190
Operating profit (EBIT)1 162166
Operating Margin 26,7%25,0%
Pre-Tax Profit (EBT)1 74,088,5
Net income1 55,577,0
Net margin 9,13%11,6%
EPS2 0,510,68
Dividend per Share2 0,410,44
Announcement Date 09/06/2021-
Previous period Next period
1 GBP in Million
2 GBP
Estimates
Finances - Leverage
Fiscal Period: June 2021 2022
Net Debt1 200162
Net Cash position1 --
Leverage (Debt / EBITDA) 1,13x0,85x
Free Cash Flow1 -45,7111
ROE (Net Profit / Equities) 18,5%20,4%
Shareholders' equity1 300377
ROA (Net Profit / Asset) 9,59%11,2%
Assets1 579688
Book Value Per Share2 5,855,70
Cash Flow per Share2 0,821,40
Capex1 13531,7
Capex / Sales 22,2%4,78%
Announcement Date 09/06/2021-
Previous period Next period
1 GBP in Million
2 GBP
Estimates
Financial Ratios
Size 2022e 2023e
Capitalization 3 783 M GBP -
Enterprise Value (EV) 3 945 M GBP 3 865 M GBP
Valuation 2022e 2023e
P/E ratio (Price / EPS) 51,3x 46,0x
Capitalization / Revenue 5,70x 5,28x
EV / Revenue 5,94x 5,50x
EV / EBITDA 20,8x 19,2x
Yield (DPS / Price) 1,26% 1,37%
Price to book (Price / BVPS) 6,12x 5,92x
Profitability 2022e 2023e
Operating Margin (EBIT / Sales) 25,0% 25,3%
Operating Leverage (Delta EBIT / Delta Sales) 0,28x 1,13x
Net Margin (Net Profit / Revenue) 11,6% 12,1%
ROA (Net Profit / Asset) 11,2% 13,6%
ROE (Net Profit / Equities) 20,4% 22,2%
Rate of Dividend 64,9% 63,0%
Balance Sheet Analysis 2022e 2023e
CAPEX / Sales   4,78% 3,12%
Cash Flow / CA 22,8% 21,5%
Capital Intensity (Assets / Revenue) 1,04x 0,89x
Financial Leverage (Net Debt / EBITDA) 0,85x 0,40x
Price Earning Ratio
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS & Dividend